PacBio Files 8-K on Financial Results and Exhibits
Ticker: PACB · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1299130
Sentiment: neutral
Topics: earnings, financial-reporting, 8-K
Related Tickers: PACB
TL;DR
**PacBio just filed an 8-K about their financial results and statements, but the actual numbers aren't in this snippet.**
AI Summary
Pacific Biosciences of California, Inc. filed an 8-K on February 15, 2024, to report on its results of operations and financial condition. The filing also indicated the furnishing of financial statements and exhibits. This specific excerpt does not detail the actual financial performance or specific dollar amounts, focusing instead on the nature of the disclosure.
Why It Matters
This 8-K signals that Pacific Biosciences is providing updated financial information to the public, which is crucial for investors to assess the company's performance and make informed decisions. It indicates transparency and compliance with SEC regulations.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure for reporting financial results and exhibits, and the provided text does not indicate any unusual or negative events.
Key Players & Entities
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — registrant
- February 15, 2024 (date) — date of report
- Delaware (location) — state of incorporation
- Menlo Park, California (location) — principal executive offices
FAQ
What is the purpose of this 8-K filing by Pacific Biosciences of California, Inc.?
The 8-K filing by Pacific Biosciences of California, Inc. on February 15, 2024, is to report on the company's results of operations and financial condition, and to furnish financial statements and exhibits, as per Item Information.
What is the earliest event date reported in this filing?
The earliest event reported in this filing occurred on February 15, 2024, as stated in the "Date of Report (Date of earliest event reported)" section.
What is the full legal name of the registrant company?
The exact name of the registrant as specified in its charter is Pacific Biosciences of California, Inc.
Where are Pacific Biosciences of California, Inc.'s principal executive offices located?
The principal executive offices of Pacific Biosciences of California, Inc. are located at 1305 O'Brien Drive, Menlo Park, California 94025.
What is the Commission File Number for Pacific Biosciences of California, Inc.?
The Commission File Number for Pacific Biosciences of California, Inc. is 001-34899.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-02-15 16:07:28
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market
Filing Documents
- pacb-20240215.htm (8-K) — 23KB
- exhibit991-earningsrelease.htm (EX-99.1) — 254KB
- 0001299130-24-000014.txt ( ) — 418KB
- pacb-20240215.xsd (EX-101.SCH) — 2KB
- pacb-20240215_lab.xml (EX-101.LAB) — 23KB
- pacb-20240215_pre.xml (EX-101.PRE) — 12KB
- pacb-20240215_htm.xml (XML) — 3KB
02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 15, 2024, Pacific Biosciences of California, Inc. (the "Company") announced its financial results for its fourth fiscal quarter and year ended December 31, 2023. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference. This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. 99.1 Press Release dated February 15, 2024, titled "PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: February 15, 2024